A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Contact:
NCT Number:
Protocol:
AAAT5185
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I/II
This study is being done to answer the following question: Is M3814 in combination with radiation therapy and avelumab safe and tolerable in patients with advanced or metastatic cancers. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your advanced or metastatic cancer. The usual approach is defined as care most people get for advanced or metastatic solid tumor.
Are you Eligible? (Inclusion Criteria)
- Are you 18 years of age or older?
- Do you have a tumor which has spread to other parts of your body or that has advanced and cannot be removed with surgery?
- Are you able to make extra visits to the clinic for treatment and evaluations?
Specialty Area(s)
Bladder Cancer , Brain and Spinal Tumors, Breast Cancer, Colon and Rectal Cancer, Esophageal Cancer, Gynecologic Cancers, Head and Neck/Oral Cancers, Kidney Cancer/Adrenal Cancer, Liver Cancer, Lung cancer, Skin cancers, Sarcomas (Bone and Soft Tissue), Stomach Cancer, Testicular Cancer, Thyroid Cancer, Immunotherapy
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
